{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:58:52Z","timestamp":1777539532924,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jpba.2017.02.061","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T16:20:00Z","timestamp":1490631600000},"page":"347-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Validation of a dried blood spot method for therapeutic drug monitoring of citalopram, mirtazapine and risperidone and its active metabolite 9-hydroxyrisperidone using HPLC\u2013MS"],"prefix":"10.1016","volume":"140","author":[{"given":"Johanna","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Oberfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Bonse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Telger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Lingg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2017.02.061_bib0005","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","volume":"380","author":"Murray","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2017.02.061_bib0010","series-title":"The Global Burden of Disease\u20142004 Update","author":"World Health Organization","year":"2008"},{"key":"10.1016\/j.jpba.2017.02.061_bib0015","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpba.2017.02.061_bib0020","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/FJC.0b013e3181379ef6","volume":"30","author":"Jimmink","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2017.02.061_bib0025","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/2042098613492366","volume":"4","author":"Kogut","year":"2013","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.jpba.2017.02.061_bib0030","first-page":"687","volume":"108","author":"Wenzel-Seifert","year":"2011","journal-title":"Dtsch. Arzteblatt Int."},{"key":"10.1016\/j.jpba.2017.02.061_bib0035","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.euroneuro.2006.08.004","volume":"17","author":"Lindenmayer","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpba.2017.02.061_bib0040","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/mas.21441","volume":"35","author":"Wagner","year":"2016","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.jpba.2017.02.061_bib0045","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajhb.22463","volume":"26","author":"McDade","year":"2014","journal-title":"Am. J. Hum. Biol."},{"key":"10.1016\/j.jpba.2017.02.061_bib0050","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jchromb.2005.03.006","volume":"820","author":"Juan","year":"2005","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.02.061_bib0055","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.aca.2004.03.042","volume":"514","author":"Pistos","year":"2004","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpba.2017.02.061_bib0060","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jchromb.2003.11.037","volume":"802","author":"Zhou","year":"2004","journal-title":"J. Chromatogr. B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2017.02.061_bib0065","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/dta.1698","volume":"7","author":"Patteet","year":"2015","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2017.02.061_bib0070","series-title":"Guideline on Bioanalytical Method Validation","author":"European Medicines Agency","year":"2011"},{"key":"10.1016\/j.jpba.2017.02.061_bib0075","series-title":"Guidance for Industry\u2014Bioanalytical Method Validation","author":"Food and Drug Administration (FDA)","year":"2013"},{"key":"10.1016\/j.jpba.2017.02.061_bib0080","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1021\/ac020361s","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2017.02.061_bib0085","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.4155\/bio.15.100","volume":"7","author":"Patteet","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2017.02.061_bib0090","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/FTD.0b013e318283eaf2","volume":"35","author":"Fisher","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2017.02.061_bib0095","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.4155\/bio.10.159","volume":"2","author":"Emmons","year":"2010","journal-title":"Bioanalysis"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516312572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708516312572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T05:58:57Z","timestamp":1535954337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708516312572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":19,"alternative-id":["S0731708516312572"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2017.02.061","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of a dried blood spot method for therapeutic drug monitoring of citalopram, mirtazapine and risperidone and its active metabolite 9-hydroxyrisperidone using HPLC\u2013MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2017.02.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}